医学
糖尿病
心力衰竭
2型糖尿病
恩帕吉菲
疾病
肾脏疾病
2型糖尿病
临床试验
内科学
重症监护医学
内分泌学
标识
DOI:10.1038/s41574-020-00453-2
摘要
Heart failure and chronic kidney disease are frequent causes of morbidity and mortality in people with type 2 diabetes mellitus. Cardiovascular outcome trials have confirmed benefits of sodium–glucose co-transporter 2 inhibitors on cardiovascular events, cardiovascular deaths, hospitalization for heart failure and renal outcomes. These benefits now extend to people with and without type 2 diabetes mellitus.
科研通智能强力驱动
Strongly Powered by AbleSci AI